Extranodal nasal type of NK/T cell lymphoma
Conditions
Interventions
A:Imed-p-asp/gdp-p-asp alternative program
B:IMED-P-asp
C:IMED-P-asp
Sponsors
Sun Yat-Sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) between the ages of 18 and 80 years; 2) untreated patients with extra-nodal NK/T cell lymphoma confirmed by histological examination; 3) there are measurable and evaluable lymphoma lesions for efficacy evaluation; 4) patients with Ann Arbor stage I and II; 5) not receiving any anti-tumor treatment; 6) normal blood routine, liver and kidney function (WBC>=3.5x10^9/L, Hb >100 g/L, PLT > 90x10^12/L); 7) the performance status of ECOG is 0-3;Life expectancy greater than 3 months; 8) no history of other malignant tumors; 9) no other serious diseases in conflict with the program; 10) no other antitumor concomitant treatment (including steroid drugs); 11) understand and are willing to participate in this clinical trial and provide a signed informed consent; 12) all patients must agree to use effective contraception during the study period and within 6 months after discontinuation of treatment. Female patients of childbearing age must have negative urine pregnancy test before treatment.
Exclusion criteria
Exclusion criteria: 1) participated in other clinical studies within the last 3 months; 2) secondary lymphoma after chemotherapy or radiotherapy for other malignant tumors; 3) transformed lymphoma; 4) Ann Arbor stage III-IV patients 5) received treatment for lymphoma before enrollment; 6) any other history of malignancy; 7) neutrophil count 2.0mg/dl); 12) clinical symptoms of brain dysfunction and serious mental illness; 13) lactating or pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| five-year survival rate; | — |
Countries
China
Contacts
Public ContactLin Tongyu
Sun Yat-Sen University Cancer Center
Outcome results
None listed